A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Xaluritamig
DRUG: Abiraterone acetate
DRUG: Docetaxel
DRUG: Cabazitaxel

Sponsor

Amgen